Answers are grounded in this paper and cite their sources.
Direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, commonly used direct oral anticoagulant (DOAC), are widely used to prevent and treat stroke and venous thromboembolic events in patients with atrial fibrillation (AF). This study aimed to assess and compare reports of adverse events associated with rivaroxaban, apixaban, and edoxaban, including hemorrhagic and non-hemorrhagic events.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: